NPI-001
Phase 1/2- Indications
- Retinitis pigmentosa, Usher syndrome
Company intelligence / Profile preview
Acuity Pharmaceuticals
Philadelphia, Pennsylvania, United Statespharmaacuity.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Acuity Pharmaceuticals developed Cand5, the first clinical use of gene-silencing technology via RNA interference targeting VEGF for wet age-related macular degeneration and diabetic eye diseases. The company also licensed N-chlorotaurine (NCT), a small molecule anti-infective with broad-spectrum activity for ophthalmic infections. Both programs showed promising safety and efficacy signals in early-phase trials before the company's acquisition by OPKO Health in June 2011.
- Therapeutic areas
- OphthalmologyInfectious Diseases
- Modalities
- Small moleculeRNA therapy (specifically RNA interference)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Pathogenics, Inc. – licensor of N-chlorotaurine ophthalmic rights
Beyond the preview
Go deeper on Acuity Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Acuity Pharmaceuticals.